Alto Neuroscience, Inc.
ANRO- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001999480
In the last 90 days, Alto Neuroscience, Inc. insiders filed 0 open-market purchases and 2 sales; 132 institutions reported holding it in 13F filings for Q3 2026, worth $991.9M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:18 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Mar 16, 2026 | Feb 3, 2025 |
| Operating expenses | $66.4M | $68.6M |
| Research and development | $45.6M | $47.0M |
| Selling, general and administrative | $20.7M | $21.6M |
| Operating income | -$66.4M | -$68.6M |
| Income tax | $0 | $0 |
| Net income | -$63.2M | -$61.4M |
| EPS, basic | $-2.19 | $-2.50 |
| EPS, diluted | $-2.19 | $-2.50 |
| Weighted shares, basic | 28.9M | 24.6M |
| Weighted shares, diluted | 28.9M | 24.6M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Mar 16, 2026 | Feb 3, 2025 |
| Cash and equivalents | $176.5M | $168.2M |
| Total current assets | $177.7M | $169.3M |
| Property, plant and equipment | $1.87M | $2.67M |
| Total assets | $184.7M | $177.5M |
| Accounts payable | $1.88M | $1.58M |
| Short-term debt | $585.0K | $0 |
| Total current liabilities | $11.3M | $10.0M |
| Long-term debt | $16.2M | $10.3M |
| Total liabilities | $33.5M | $26.1M |
| Shareholders' equity | $151.1M | $151.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Mar 16, 2026 | Feb 3, 2025 |
| Operating cash flow | -$51.8M | -$47.4M |
| Capital expenditures | $24.0K | $2.08M |
| Free cash flow | -$51.8M | -$49.5M |
| Depreciation and amortization | – | $502.0K |
| Stock-based compensation | $8.11M | $7.63M |
| Investing cash flow | -$24.0K | -$2.08M |
| Financing cash flow | $60.1M | $135.7M |
| Net change in cash | $8.26M | $86.2M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 5, 2026 | 40.1M | +29.1% | SEC |
| Aug 7, 2026 | 39.2M | +44.9% | SEC |
| May 8, 2026 | 35.1M | +29.6% | SEC |
| Mar 9, 2026 | 31.9M | +18.0% | SEC |
| Nov 7, 2025 | 31.1M | +15.2% | SEC |
| Aug 8, 2025 | 27.1M | +0.4% | SEC |
| May 9, 2025 | 27.1M | +0.7% | SEC |
| Mar 17, 2025 | 27.1M | +0.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.